Maeurer M J, Martin D M, Castelli C, Elder E, Leder G, Storkus W J, Lotze M T
Department of Surgery, University of Pittsburgh Medical Center, PA 15261, USA.
Cancer Immunol Immunother. 1995 Aug;41(2):111-21. doi: 10.1007/BF01527407.
Human renal cell cancer (RCC) is clearly responsive to immunotherapy. Clinical responses may be mediated by "non-specific" (e.g. natural killer, NK, cells) or "specific" MHC-class-I-restricted tumor-specific CD8+ T lymphocytes. Typically RCC progresses, however, despite significant infiltration of various lymphoid cells. We examined freshly isolated RCC tumor-infiltrating lymphocytes (TIL) derived from seven RCC patients for cytokine expression by the polymerase chain reaction (PCR). Established RCC tumor cell lines derived from these RCC patients were negative for interleukin-2 (IL-2), IL-4, IL-10, and interferon gamma and found to be positive for tumor necrosis factor alpha (TNF alpha), IL-6, IL-1 beta, granulocyte/macrophage-colony-stimulating factor (GM-CSF), and transforming growth factor beta 1 (TGF beta 1) message as detected by PCR. An identical pattern of cytokine mRNA expression was identified in other long-term RCC lines and in normal human kidney cells upon culture, but not in two Wilms tumor cell lines tested. Short-term-, and long-term-established RCC lines, but not Wilms tumor lines, secreted substantial levels of GM-CSF, TNF alpha, IL-1 beta, and IL-6 as detected by enzyme-linked immunosorbent assay. Both RCC lines and Wilms tumor lines secreted TGF beta 1. In comparison, normal kidney cells secreted IL-6 and GM-CSF, but not IL-1 beta, or TFG beta 1 under identical in vitro cell culture conditions. We applied PCR-based methods to characterize the cytokine mRNA expression pattern in immune cells infiltrating into renal cell cancer without the need for expansion of such effector cells in vitro. Examining freshly collected RCC TIL by PCR from patients with primary cell cell cancer, we could demonstrate that such cells, but not lympho-mononuclear cells harvested from normal human kidney tissue, typically exhibit IL-4 and IL-10 mRNA expression.
人类肾细胞癌(RCC)对免疫疗法有明显反应。临床反应可能由“非特异性”(如自然杀伤细胞,NK细胞)或“特异性”MHC-I类限制性肿瘤特异性CD8 + T淋巴细胞介导。然而,典型的肾细胞癌会进展,尽管有各种淋巴细胞的大量浸润。我们通过聚合酶链反应(PCR)检测了从7例肾细胞癌患者新鲜分离的肿瘤浸润淋巴细胞(TIL)的细胞因子表达。从这些肾细胞癌患者中建立的肾细胞癌肿瘤细胞系白细胞介素-2(IL-2)、IL-4、IL-10和干扰素γ呈阴性,通过PCR检测发现肿瘤坏死因子α(TNFα)、IL-6、IL-1β、粒细胞/巨噬细胞集落刺激因子(GM-CSF)和转化生长因子β1(TGFβ1)呈阳性。在其他长期肾细胞癌系和培养后的正常人肾细胞中鉴定出相同的细胞因子mRNA表达模式,但在两个测试的肾母细胞瘤细胞系中未发现。通过酶联免疫吸附测定法检测,短期和长期建立的肾细胞癌系,但不是肾母细胞瘤系,分泌大量水平的GM-CSF、TNFα、IL-1β和IL-6。肾细胞癌系和肾母细胞瘤系均分泌TGFβ1。相比之下,在相同的体外细胞培养条件下,正常肾细胞分泌IL-6和GM-CSF,但不分泌IL-1β或TFGβ1。我们应用基于PCR的方法来表征浸润肾细胞癌的免疫细胞中的细胞因子mRNA表达模式,而无需在体外扩增此类效应细胞。通过PCR检测原发性细胞癌患者新鲜采集的肾细胞癌TIL,我们可以证明此类细胞,而不是从正常人肾组织中收获的淋巴细胞单核细胞,通常表现出IL-4和IL-10 mRNA表达。